David Russell

Institute for Neurodegenerative Disorders — United States

Medicine · Health Sciences

50h-index12.3kcitations165works9.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Parkinson's Disease Mechanisms and Treatments(31), Neurological disorders and treatments(25), Neuroscience and Neuropharmacology Research(20), Genetics and Neurodevelopmental Disorders(19), Alzheimer's disease research and treatments(17)

Publications163 total

Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study
EBioMedicine·2025· 13 citedOpen Access
Correction: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study
Neuropsychopharmacology·2025Open Access
Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study
Neuropsychopharmacology·2025· 1 citedOpen Access
In Vivo Head-to-Head Comparison of [<sup>18</sup>F]GTP1 with [<sup>18</sup>F]MK-6240 and [<sup>18</sup>F]PI-2620 in Alzheimer Disease
Journal of Nuclear Medicine·2025· 2 citedOpen Access
Discovery and clinical translation of ceperognastat, an O‐GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease
Alzheimer s & Dementia Translational Research & Clinical Interventions·2024· 17 citedOpen Access
Multiple sclerosis in LRRK2 G2019S Parkinson’s disease and isolated nigral degeneration in a homozygous variant carrier
Frontiers in Neurology·2024· 3 citedOpen Access
Long-Term Dementia Risk in Parkinson Disease
Neurology·2024· 55 citedOpen Access
Combining alpha-synuclein PET and seeded-amplification to improve diagnostic accuracy of Multiple System Atrophy
2024· 1 citedOpen Access
Glutamatergic Dysfunction in Autism Spectrum Disorder (P1-8.001)
Neurology·2024
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
Nature Communications·2023· 124 citedOpen Access
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
Neurology·2023· 97 citedOpen Access
Predictive value of abbreviated olfactory tests in prodromal Parkinson disease
npj Parkinson s Disease·2023· 9 citedOpen Access
Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration
Acta Neuropathologica Communications·2023· 15 citedOpen Access
Machine learning enhances prediction of plants as potential sources of antimalarials
Frontiers in Plant Science·2023· 9 citedOpen Access
PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH
Alzheimer s & Dementia·2022
In Vivo Head‐To‐Head Comparison of [<sup>18</sup>F]GTP1 and [<sup>18</sup>F]PI2620 in Alzheimer’s Disease
Alzheimer s & Dementia·2022· 1 cited
PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH
Alzheimer s & Dementia·2022
In Vivo Head‐To‐Head Comparison of [<sup>18</sup>F]GTP1 and [<sup>18</sup>F]PI2620 in Alzheimer’s Disease
Alzheimer s & Dementia·2022
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
npj Parkinson s Disease·2022· 18 citedOpen Access
Serial olfactory testing for the diagnosis of prodromal Parkinson's disease in the PARS study
Parkinsonism & Related Disorders·2022· 11 cited
page 1 of 9Next →

Frequent Co-authors

Kenneth Marek(13), John Seibyl(10), Ronald S. Duman(9), Andrew Siderowf(7), Olivier Barret(7), Eric J. Nestler(7), Danna Jennings(6), Robert A. Hauser(5), Brit Mollenhauer(4), Todd Sherer(4), Cathi-Ann Thomas(4), Irene Hegeman Richard(4), O M Rosen(4), Catharine H. Duman(4), Alberto J. Espay(4), Gilles Tamagnan(4), David Alagille(4), Tanya Simuni(3), Sohini Chowdhury(3), Werner Poewe(3)